首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1461326

肿瘤药物市场，依配销通路、药物类型、癌症类型、治疗方法、给药途径、地理位置。

Oncology Drugs Market, By Distribution Channel, Drug Type, Cancer Type, By Therapy, By Route of Administration, By Geography .

出版日期: 2024年03月19日 | 出版商:

Coherent Market Insights | 英文 188 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2024年肿瘤药物市值为2,315.6亿美元，预计到2031年将达到5,329.1亿美元，2024年至2031年年复合成长率（CAGR）为12.6%。

报告范围		报告详情
基准年：	2023年	2023/2024 年市场规模：	2315.6 亿美元
历史数据：	2019年至2023年	预测期：	2024年至2031年
预测期间 2023/2024 至 2030/2031 年复合成长率：	12.60%	2030/2031 价值预测：	5329.1 亿美元

肿瘤药物市场占有率 (%)，按地区，2024 年

肿瘤药物是指用于治疗癌性肿瘤的药物。由于各种癌症盛行率不断上升，过去几年全球肿瘤药物市场一直稳定成长。据世界卫生组织称，自2000年以来，癌症负担几乎翻了一番，预计到2040年全球癌症负担将增加50%。主要因素用于肿瘤药物。此外，老年人口的增长和生活习惯的改变，如吸烟、饮酒、不良饮食和缺乏体力活动，也增加了癌症的风险，从而增加了肿瘤药物的销售。新型药物分子和疗法的强大管道以及标靶疗法的出现正在进一步促进市场扩张。然而，高昂的治疗成本仍然是一个瓶颈，限制了癌症药物的更广泛采用。

市场动态：

全球肿瘤药物市场受到全球各种癌症类型盛行率上升的推动。根据提供全球癌症统计数据的互动式网路平台 GLOBOCAN 的数据，2020 年全球约有 1,930 万新发癌症病例，1,000 万人因癌症死亡。对标靶治疗的需求不断增长以及仿製药的容易获得为市场提供了巨大的成长机会。然而，严格的监管政策、药物开发的高研发成本以及临床试验中药物失败频繁等因素阻碍了市场的成长。此外，重磅药物的专利到期对主要参与者的收入产生负面影响。儘管如此，亚太地区的新兴市场正在开闢新的途径，在意识不断增强、医疗保健支出和对优质癌症治疗的需求的推动下，提供潜在的未来机会。

研究的主要特点：

该报告对全球肿瘤药物市场进行了深入分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
它阐明了不同细分市场的潜在收入成长机会，并解释了该市场有吸引力的投资主张矩阵。
这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
它根据以下参数描述了全球肿瘤药物市场的主要参与者——公司亮点、产品组合、主要亮点、财务表现和策略。
该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球肿瘤药物市场报告迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
利害关係人可以透过用于分析全球肿瘤药物市场的各种策略矩阵轻鬆做出决策。

介绍
北美洲
我们
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
拉丁美洲其他地区
欧洲
英国
德国
义大利
法国
西班牙
俄罗斯
欧洲其他地区
亚太地区
中国
印度
日本
东协
澳洲
韩国
亚太地区其他地区
中东
海湾合作委员会
以色列
中东其他地区
非洲
北非
中非
南非

第 11 章：竞争格局

热图分析
公司简介
- Pfizer Inc.
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Bristol-Myers Squibb
- Amgen Inc.
- Sanofi AG
- F. Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
- Astellas Pharma Inc.
- AbbVie Inc.
- Takeda Pharmaceutical Company
- Daiichi Sankyo

第 12 章：分析师观点

命运之轮
分析师观点
连贯的机会图

第 13 章：参考文献与研究方法

参考
研究方法论

简介目录

Product Code: CMI2332

The oncology drugs market is estimated to be valued at USD 231.56 Bn in 2024 and is expected to reach USD 532.91 Bn by 2031, growing at a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 231.56 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	12.60%	2030/2031 Value Projection:	US$ 532.91 Bn

Oncology Drugs Market Share (%), By Region, 2024

Oncology drugs refer to medications that are used for treating cancerous tumors. The global oncology drugs market has been witnessing steady growth over the past few years owing to the rising prevalence of various types of cancers. According to the World Health Organization, the cancer burden has nearly doubled since 2000 and is expected to grow by 50% globally by 2040. The increasing incidences of lung cancer, colorectal cancer, breast cancer, and prostate cancer are the major factors fueling the demand for oncology drugs. Furthermore, the growing geriatric population and changing lifestyle habits such as tobacco smoking, alcohol consumption, poor diet, and lack of physical activity have also raised the risk of developing cancer which has augmented the sales of oncology medications. A robust pipeline of novel drug molecules and therapies along with the emergence of targeted therapies are further catalyzing market expansion. However, high treatment cost remains a bottleneck, restraining the broader adoption of cancer medications.

Market Dynamics:

The global oncology drugs market is driven by the rising prevalence of various cancer types worldwide. As per GLOBOCAN, an interactive web-based platform presenting global cancer statistics, there were around 19.3 million new cancer cases and 10 million cancer deaths globally in 2020. Lung cancer remains the leading cause of cancer death. The increasing demand for targeted therapies and easy availability of generic medications are providing huge growth opportunities in the market. However, factors such as stringent regulatory policies, high R&D costs involved in drug development, and frequent drug failures in clinical trials are impeding the market growth. Furthermore, patent expiry of blockbuster drugs is negatively impacting the revenues of major players. Nonetheless, emerging markets in Asia Pacific are opening up new avenues by offering potential future opportunities driven by growing awareness, healthcare spending, and demand for quality cancer treatment.

Key Features of the Study:

This report provides an in-depth analysis of the global oncology drugs market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global oncology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study includes Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, F. Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., GSK plc, Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, BeiGene LTD, Astellas Pharma Inc., AbbVie Inc., Takeda Pharmaceutical Company, and Daiichi Sankyo
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oncology drugs market

Market Segmentation

Drug Type
- Cytotoxic Drugs
- Alkylating Agents
- Antimetabolites
- Others
- Targeted Drugs
- Monoclonal Antibodies
- Tyrosine Kinase Inhibitors
- Others
- Hormonal Drugs
- Ovarian Function Blockers
- Estrogen Production Blockers
- Others
Cancer Type:
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Blood Cancer
- Bladder Cancer
- Other
Therapy:
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others
Route of Administration:
- Oral
- Parental
- Intramuscular
- Intravenous
- Subcutaneous
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Pfizer Inc.
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Amgen Inc.
- Sanofi AG
- F.Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
- Astellas Pharma Inc.
- AbbVie Inc.
- Takeda Pharmaceutical Company
- Daiichi Sankyo

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Preview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Cancer Type
- Market Snapshot, By Therapy
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Pipeline Analysis
Patent Expiry List (2017-2030)
Investments for R&D
Reimbursement Scenario
Mergers & Acquisitions
Collaborations
Epidemiology
PEST Analysis

4. Global Oncology Drugs Market - Impact of Coronavirus (COVID-19) Pandemic:

Overall Impact
COVID-19 Impact on the Market

5. Global Oncology Drugs Market, By Drug Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Cytotoxic Drug
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Alkylating Agents
Antimetabolites
Others
Targeted Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Others
Hormonal Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Ovarian Function Blockers
Estrogen Production Blockers
Others
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Oncology Drugs Market, By Cancer Type,2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Lung Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Breast Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Colorectal Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Prostate Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Blood Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Bladder Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Oncology Drugs Market, By Therapy, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Oncology Drugs Market, By Route of Administration, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Parental
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Intramuscular
- Intravenous
- Subcutaneous

9. Global Oncology Drugs Market, By Distribution Channel, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

10. Global Oncology Drugs Market, By Region, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2020-2031
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
North Africa
Central Africa
South Africa

11. Competitive Landscape

Heat Map Analysis
Company Profile
- Pfizer Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Bristol-Myers Squibb
- Amgen Inc.
- Sanofi AG
- F. Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
- Astellas Pharma Inc.
- AbbVie Inc.
- Takeda Pharmaceutical Company
- Daiichi Sankyo